trending Market Intelligence /marketintelligence/en/news-insights/trending/ZYOUNUhCF8lsqKWwYEbgrg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In this list

Liquidia Technologies prices $34.5M common stock offering

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Liquidia Technologies prices $34.5M common stock offering

Liquidia Technologies Inc. priced an underwritten public offering of 3 million common shares at $11.50 apiece to raise $34.5 million in gross proceeds.

The biopharmaceutical company has also granted underwriters an option to buy up to an additional 450,000 shares.

Morrisville, N.C.-based Liquidia expects to close the offering March 25, subject to closing conditions.

Jefferies and Cowen are the joint book-running managers, with Needham & Co. and Wedbush PacGrow as co-managers for the offering.

Liquidia develops human therapeutics using its proprietary print technology, a particle engineering platform. Its lead product candidate LIQ861 — an inhaled dry powder formulation of treprostinil — is in a phase 3 study to treat pulmonary arterial hypertension.